From GlobeNewswire: 2025-06-16 09:32:00

The Chemiluminescence Immunoassay (CLIA) Market was valued at USD 11.76 billion in 2023, projected to reach USD 17.72 billion by 2032, with a CAGR of 4.68%. Factors driving growth include the rise in chronic diseases, demand for sensitive diagnostics, and expanded clinical lab infrastructure in emerging markets. In the US, the market reached USD 3.66 billion in 2023, expected to maintain strong momentum.

High-sensitivity CLIA assays are popular in oncology, endocrinology, and infectious disease testing due to their precision and multiplexing abilities. The global rise in chronic diseases and emphasis on early detection drives market growth. Major players in the CLIA market include Roche, Danaher, Siemens, and Abbott. Consumables accounted for 65.7% of market revenue in 2023, with blood samples dominating the market.

Regionally, North America led the CLIA market in 2023, driven by big industry players, insurance coverage, and developed lab infrastructure. Asia Pacific is expected to be the fastest-growing market, fueled by rising infectious diseases, decentralized testing, and increased healthcare access. SNS Insider is a leading market research agency providing accurate data and insights for confident decision-making. Contact Vice President Jagney Dave for more information.



Read more at GlobeNewswire: Chemiluminescence Immunoassay Market to Hit USD 17.72